CLINICAL INVESTIGATIONS ON URINARY FIBRINOLYSIS IN BLADDER CARCINOMA

Abstract

Fibrin/fibrinogen degradation products (FDP) and plasminogen activator activity were measured by means of latex agglutination test and standard fibrin plate method respectively on urine specimens from 60 patients with bladder carcinoma, and the following results were obtained.
1) Urinary FDP was positive in 25 of 28 pretreated cases (89.3%), but it was not detected in 10 of 14 cases (71.4%) treated by neocarzinostatin and in all of 8 cases trated by transurethral resection and intravesical infusion of mitomycin C. It was positive in 9 of 10 cases performed total cystectomy with urinary diversion.
2) Urinary plasminogen activator activity showed no definite tendency in pretreated cases but tended to be normalized or decreased after treatment.
3) Urinary FDP had a close relation to grade and stage of carcinoma, but urinary plasminogen activator activity had no relation with urinary FDP and grade or stage of carcinoma.
4) Recarcification time, Quick's prothrombin time and Duke's bleeding time were in normal range in most cases and thrombosis or hemorrhagic tendency was not observed in all cases.
The results demonstrated that urinary FDP originating in tumor was detected in most patients with bladder carcinoma, however, urinary plasminogen activator originating mostly in the kidney had no definit relationship with bladder carcinoma. The results also suggests the urinary FDP may be useful to diagnose the grade and stage of tumor, to estimate the effect of reatment and to forsee the recurrence of bladder carcinoma.